This study aimed to investigate the efficacy and safety of the combination of nivolumab, anti-PD-1 antibody, and RT in patients with HER2-negative metastatic breast cancer who need palliative RT for bone metastasis. The gene discussed is ERBB2; the disease is bone metastasis.